com Development pipeline Compound Areas under investigation Estimated filing date Stage of development MAA NDA PC 1 2 3 Cardiovascular Exanta prevention of VTE Launched Filed Exanta SC formulation prevention of VTE Launched 2007 Galida diabetes metabolic syndrome 2007 2007 AZD6140 arterial thrombosis 2007 2007 AZD7009 AF conversion 2007 2007 AZD7009 AF maintenance 2007 2007 AZD9684 thrombosis 2007 2007 AZD0837 thrombosis 2007 2007 AZD7806 dyslipidaemia 2007 2007 AZD4619 dyslipidaemia 2007 2007 AZD6610 dyslipidaemia diabetes 2007 2007 AZD8294 dyslipidaemia 2007 2007 AZD8677 dyslipidaemia diabetes 2007 2007 AZD8450 dyslipidaemia 2007 2007 AZD6370 diabetes 2007 2007 Gastrointestinal AZD0865 acid-related GI disease 2007 2007 AZD7371 functional GI disease 2007 2007 AZD3355 GERD 2007 2007 AZD9343 GERD 2007 2007 AZD5745 acid-related GI disease 2007 2007 AZD8081 functional GI disease 2007 2007 Neuroscience Cerovive stroke 2H 2006 2H 2006 AZD7371 overactive bladder 2007 2007 AZD8129 AR-A2 anxiety depression 2007 2007 AZD4282 neuropathic pain 2007 2007 AZD3102 Alzheimers disease 2007 2007 AZD1080 Alzheimers disease 2007 2007 AZD9272 neuropathic pain 2007 2007 AZD2327 anxiety 2007 2007 AZD5904 multiple sclerosis 2007 2007 AZD6538 neuropathic pain 2007 2007 Oncology IressaNSCLC WithdrawnLaunched ZD6474 solid tumours 2007 2007 ZD4054 solid tumours 2007 2007 AZD2171 solid tumours 2007 2007 AZD3409 solid tumours 2007 2007 AZD0530 solid tumours and haematological malignancies 2007 2007 AZD5438 solid tumours 2007 2007 AZD6244 solid tumours 2007 2007 ZD6126 solid tumours 2007 2007 AZD4440 solid tumours 2007 2007 AZD9935 solid tumours 2007 2007 AZD0424 solid tumours 2007 2007 AZD1152 solid tumours and haematological malignancies 2007 2007 AZD4769 solid tumours 2007 2007 AZD3841 solid tumours 2007 2007 AZD8931 solid tumours 2007 2007 Respiratory and Inflammation AZD9056 rheumatoid arthritis 2007 2007 AZD9056 osteoarthritis 2007 2007 The table on the right provides summary details AZD8309 rheumatoid arthritis 2007 2007 of the new chemical entities currently in our pipeline.
AZD8955 osteoarthritis 2007 2007 Full details, including line extensions, can be found AZD8309 COPD 2007 2007 in the separate AstraZeneca Annual Report and AZD3778 asthma rhinitis 2007 2007 Form 20-F Information 2004 or on our website.
AZD9056COPD 2007 2007 AZD3342 COPD 2007 2007 Abbreviations used in pipeline table: AZD6067 COPD 2007 2007 AF atrial fibrillation AZD2098 asthma 2007 2007 COPD chronic obstructive pulmonary disease AZD1981 asthma 2007 2007 GERD gastro-oesophageal reflux disease AZD0902 rheumatoid arthritis 2007 2007 GI gastrointestinal AZD6703 rheumatoid arthritis 2007 2007 MAA marketing authorisation application Europe AZD6357 osteoarthritis 2007 2007 NDA new drug application US AZD7928 COPD 2007 2007 NSCLC non-small cell lung cancer AZD2914 COPD 2007 2007 PC pre-clinical: candidate drug accepted AZD2392 asthma rhinitis 2007 2007 for development but not yet administered AZD1744 asthma rhinitis 2007 2007 to man AZD5672 rheumatoid arthritis 2007 2007 SC subcutaneous VTE venous thromboembolism Discussions are ongoing with the FDA to determine if there is now a realistic prospect of bringing Exanta to the US market.
The NDA file remains open.
